PROBUCOL REDUCES PLASMA AND AORTIC-WALL OXYSTEROL LEVELS IN CHOLESTEROL-FED RABBITS INDEPENDENTLY OF ITS PLASMA-CHOLESTEROL LOWERING EFFECT

To understand further the antiatherogenic mechanism of probucol, the antioxidant effect of this agent was studied on specific cholesterol oxidation products in plasma and aortic wall in equally hypercholesterolemic New Zealand white rabbits. In order to maintain equal plasma total cholesterol levels, five control rabbits (C group) received a 1% followed by a 0.5% cholesterol enriched diet, while the probucol treated rabbits (C+P group) received a graded increase in the cholesterol supplemented diet from 1% to 3%; probucol supplementation was constant at 1%. After 9 weeks of feeding, the plasma oxysterols, cholest-5-ene-3beta,7alpha-diol, cholest-5-ene-3beta,7beta-diol, 5,6beta-epoxy-5alpha-cholestan-3beta-ol, 5,6alpha-epoxy-5alpha-cholestan-3alpha-ol and 5alpha-cholestane-3beta,5,6beta-triol significantly increased over baseline levels in both experimental groups. However, the increase in all these products in plasma was 20-60% less in the C+P group than the C group (P < 0.05). Furthermore, the C+P aortic wall cholesterol oxide concentrations were 50-90% less than the C group (P < 0.05). The oxysterol pattern of the aortic wall was similar to plasma. Additionally, the aortic wall cholesterol content in the C+P group was 50% less than the C group (P < 0.05). The plasma cholesterol levels were not significantly different at any time point during the study and the cholesterol oxide content in the diets was the same. These results are consistent with the contention that the antioxidant properties of probucol serve as the basis for its antiatherogenic effects in vivo.